| abstract |
This invention relates to a novel form of a serotonin h5-= 1B-receptor antagonist, namely a novel form of a salt of (R)-N-[5-melhyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphiyl]-4-morpholinobenzamide referred to as (R)-N-|5-methyl-8-(4-metliylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl]-4-morfolinobenzamide monohydrobromide Form A. The invention also relates to processes for preparation of said of Form A, which form has a potential use after suitable pharmaceutical formulation in medical treatment, preferably in CNS disorders, over active bladder or vasospam, or growth control of tumors. |